Ligand Pharmaceuticals
LGND
266 hedge funds and large institutions have $3.04B invested in Ligand Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 103 increasing their positions, 87 reducing their positions, and 23 closing their positions.
384% more call options, than puts
Call options by funds: $26.7M | Put options by funds: $5.51M
48% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 23
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
18% more repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 87
16% more capital invested
Capital invested by funds: $2.61B → $3.04B (+$424M)
4% more funds holding
Funds holding: 257 → 266 (+9)
1.81% more ownership
Funds ownership: 189.26% → 191.07% (+1.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$66.8M |
| 2 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
+$22M |
| 3 |
Russell Investments Group
London,
United Kingdom
|
+$11.5M |
| 4 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$11.3M |
| 5 |
CM
Castleark Management
Chicago,
Illinois
|
+$8.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
-$48.8M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$15.6M |
| 3 |
GAM
Gotham Asset Management
New York
|
-$12.5M |
| 4 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
-$9.69M |
| 5 |
State of New Jersey Common Pension Fund D
Trenton,
New Jersey
|
-$7.85M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PG
276
PEAK6 Group
Chicago,
Illinois
| – | -$408K | -5,837 | Closed |
|
|
FO
277
FT Options
Chicago,
Illinois
| – | -$379K | -5,740 | Closed |
|
|
AIM
278
Assured Investment Management
New York
| – | -$291K | -4,400 | Closed |
|
279
Janney Montgomery Scott
Philadelphia,
Pennsylvania
| – | -$259K | -3,929 | Closed |
|
|
FCBT
280
First Citizens Bank & Trust
Raleigh,
North Carolina
| – | -$231K | -3,501 | Closed |
|
|
BC
281
Brinker Capital
Berwyn,
Pennsylvania
| – | -$202K | -3,067 | Closed |
|
|
PAM
282
Paradigm Asset Management
New York
| – | -$53.2K | -806 | Closed |
|
|
QT
283
Quantbot Technologies
New York
| – | -$44K | -672 | Closed |
|
|
AIM
284
Arcadia Investment Management
Kalamazoo,
Michigan
| – | -$25K | -377 | Closed |
|
|
CAG
285
Crestwood Advisors Group
Boston,
Massachusetts
| – | -$6K | -88 | Closed |
|
|
PA
286
Parallel Advisors
San Francisco,
California
| – | +$210 | +3 | New |
|
LGND Hedge Fund Activity: Q2 2017 in Review
266 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q2 2017, worth a combined $3.04B — up 16% from $2.61B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new LGND positions and 23 closed out — a net gain of 11 holders — while 103 added to existing stakes and 87 trimmed.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $66.8M. The largest seller was Scopia Capital Management, cutting an estimated $48.8M.
- 266 institutional investors held Ligand Pharmaceuticals (LGND) as of Q2 2017, up from 257 in Q1 2017.
- Funds reported $3.04B of Ligand Pharmaceuticals stock for Q2 2017, up 16% quarter-over-quarter.
- 34 funds opened new Ligand Pharmaceuticals positions in Q2 2017 and 23 closed out, a net change of +11 holders.
- The largest Ligand Pharmaceuticals buyer in Q2 2017 was Janus Henderson Group, an estimated $66.8M added.
- The largest Ligand Pharmaceuticals seller in Q2 2017 was Scopia Capital Management, an estimated $48.8M sold.
Based on aggregated 13F filings for Q2 2017.